An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
VERDICT
The label
Markup
read at $103.06
Abbott Laboratories holds its Markup at $103.06.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-24
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price
$103.06
Valuation
33.35 trailing · 16.99 forward price to earnings
Values screen
PASS· score 87.2
Beta
0.61
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 23% discount to our $126.21 fair value, moderate competitive moat, 13.00% revenue growth.
Read at
$103.06
33.35 P/E · 16.99 fwd
Our fair value
$126.21
23% discount
Analyst target (avg)
$119.00
+15% to current
Target low $103.00Analyst target rangeTarget high $135.00
▲ current $103.06 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$103.06
you are here
Conservative
$100.07
-3%
Analyst avg
$119.00
+15%
Our fair value
$126.21
+22%
Analyst high
$135.00
+31%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
13.00%
Profit margin
11.65%
Debt to equity
64.77
Analyst consensus
Buy · 24 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 16.0% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.7% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 19.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.7% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Daily health tools built across four steady segments
Walk into any hospital or pharmacy and the odds are high that an Abbott product sits on the shelf or in the kit. The company sells diagnostics, nutrition, established drugs and medical devices in markets that rarely stop needing them.
Revenue is climbing 13 percent a year with a 12 percent profit margin and a moderate moat. At 16.6 times forward earnings the shares sit 25 percent below our fair value of 126 dollars while still clearing the ethical screen, which is why the name registers as an opportunity.
The moderate moat leaves room for rivals to chip away on pricing and new devices, and any slowdown in elective procedures can trim growth faster than the multiple suggests. Twenty four analysts see 119 dollars as fair, so the gap is real but not guaranteed.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
ABT trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. Entered 2026-07-20 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-20Markup · changed$100.68+10.6%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119.
2026-07-18Distribution$91.07+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119.
2026-07-16Distribution$91.07+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $119. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Distribution$91.07+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$91.07Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.